JP2011524858A - 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法 - Google Patents

抗ｐｓｇｌ−１抗体並びにその同定及び使用方法 Download PDF

Info

Publication number
JP2011524858A
JP2011524858A JP2011509761A JP2011509761A JP2011524858A JP 2011524858 A JP2011524858 A JP 2011524858A JP 2011509761 A JP2011509761 A JP 2011509761A JP 2011509761 A JP2011509761 A JP 2011509761A JP 2011524858 A JP2011524858 A JP 2011524858A
Authority
JP
Japan
Prior art keywords
psgl
antibody
selectin
binding
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011509761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524858A5 (enExample
Inventor
アルヴァレス，リチャード
ローリンズ，スコット
Original Assignee
セレクシーズ ファーマスーティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレクシーズ ファーマスーティカルズ コーポレーション filed Critical セレクシーズ ファーマスーティカルズ コーポレーション
Publication of JP2011524858A publication Critical patent/JP2011524858A/ja
Publication of JP2011524858A5 publication Critical patent/JP2011524858A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011509761A 2008-05-15 2009-05-15 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法 Pending JP2011524858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12779108P 2008-05-15 2008-05-15
US61/127,791 2008-05-15
PCT/US2009/044188 WO2009140623A2 (en) 2008-05-15 2009-05-15 Anti-psgl-1 antibodies and methods of identification and use

Publications (2)

Publication Number Publication Date
JP2011524858A true JP2011524858A (ja) 2011-09-08
JP2011524858A5 JP2011524858A5 (enExample) 2012-05-10

Family

ID=41316376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509761A Pending JP2011524858A (ja) 2008-05-15 2009-05-15 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法

Country Status (6)

Country Link
US (2) US7833530B2 (enExample)
EP (2) EP3388527A1 (enExample)
JP (1) JP2011524858A (enExample)
AU (1) AU2009246166B2 (enExample)
CA (1) CA2724415C (enExample)
WO (1) WO2009140623A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014062091A (ja) * 2012-08-31 2014-04-10 Asahi Kasei Medical Co Ltd 基材及びデバイス
JP2020518275A (ja) * 2017-05-03 2020-06-25 バイオマリン ファーマシューティカル インコーポレイテッド 造血幹細胞の形質導入のための改善されたレンチウイルス
JP2021529753A (ja) * 2018-06-29 2021-11-04 ヴェルソー セラピューティクス， インコーポレイテッド 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法
JP2022535550A (ja) * 2019-06-04 2022-08-09 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377440B2 (en) 2006-12-01 2013-02-19 Selexys Pharmaceuticals Corporation Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
EP3222635A1 (en) * 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
CN116063522A (zh) * 2011-06-13 2023-05-05 美国全心医药生技股份有限公司 抗psgl-1抗体及其用途
JP7244422B2 (ja) 2017-01-11 2023-03-22 ブリストル－マイヤーズ スクイブ カンパニー Ｐｓｇｌ－１アンタゴニスト及びその使用
SG11201907848YA (en) 2017-03-14 2019-09-27 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
MX2020009786A (es) 2018-03-21 2020-10-12 Five Prime Therapeutics Inc Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
CN118994395A (zh) 2018-07-20 2024-11-22 皮埃尔法布雷医药公司 Vista受体
KR102242285B1 (ko) * 2019-10-02 2021-04-20 코아스템(주) 중간엽줄기세포의 전신홍반루푸스 치료효과 예측용 바이오마커 조성물
CN113322223B (zh) * 2021-06-03 2023-09-12 重庆市畜牧科学院 富硒酵母基因工程菌及其表面展示系统及其构建方法
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途
CN120265323A (zh) * 2022-09-13 2025-07-04 泰克斯制药公司 抗体、组合物和治疗方法
WO2025191538A1 (en) * 2024-03-14 2025-09-18 Tetherex Pharmaceuticals Corporation Pharmaceutical compositions and methods of treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7016A (en) * 1850-01-15 Mill for grinding
JP2007501021A (ja) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20020031508A1 (en) * 2000-05-19 2002-03-14 Wagner Denisa D. Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
US20070160601A1 (en) * 2005-12-09 2007-07-12 Angela Widom Neutralizing antibodies against primate psgl-1 and uses therefor
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
EP2029621A2 (en) * 2006-06-07 2009-03-04 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7016A (en) * 1850-01-15 Mill for grinding
JP2007501021A (ja) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014000168; 平田多佳子: 'ＰＳＧＬ-１と皮膚特異的ケモカインＣＴＡＣＫ／ＣＣＬ２７の相互作用' 日本免疫学会総会・学術集会記録 , 20031105, ｐ．２３３　２-Ｊ-Ｗ３０-４-Ｏ／Ｐ *
JPN6014046886; Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　Ｂｉｏｐｈｙｓｉｃａｌ　Ｒｅｓｅａｒｃｈ　Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．３５０，　Ｎｏ．３, 2006, ｐｐ．５０８-５１３ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014062091A (ja) * 2012-08-31 2014-04-10 Asahi Kasei Medical Co Ltd 基材及びデバイス
JP2020518275A (ja) * 2017-05-03 2020-06-25 バイオマリン ファーマシューティカル インコーポレイテッド 造血幹細胞の形質導入のための改善されたレンチウイルス
JP2021529753A (ja) * 2018-06-29 2021-11-04 ヴェルソー セラピューティクス， インコーポレイテッド 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法
JP2022535550A (ja) * 2019-06-04 2022-08-09 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
JP7716992B2 (ja) 2019-06-04 2025-08-01 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用

Also Published As

Publication number Publication date
US20110081666A1 (en) 2011-04-07
WO2009140623A3 (en) 2010-01-28
EP2291536A2 (en) 2011-03-09
CA2724415A1 (en) 2009-11-19
WO2009140623A2 (en) 2009-11-19
EP2291536A4 (en) 2013-02-27
AU2009246166B2 (en) 2014-09-18
US7833530B2 (en) 2010-11-16
CA2724415C (en) 2016-09-13
EP3388527A1 (en) 2018-10-17
US20090285812A1 (en) 2009-11-19
AU2009246166A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AU2009246166B2 (en) Anti-PSGL-1 antibodies and methods of identification and use
ES2356190T3 (es) Anticuerpos injertados con cdr humanos y fragmentos de antícuerpo de los mismos.
JP6012473B2 (ja) 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
US6245332B1 (en) Modulation of systemic memory T cell trafficking
KR20150047593A (ko) 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법
JPH03201995A (ja) 活性内皮細胞に対するモノクローナル抗体、該モノクローナル抗体およびそれらの抗原を用いた医薬品および治療法ならびに該モノクローナル抗体を用いた診断法
JP7671887B2 (ja) 抗第ＩＸ因子Ｐａｄｕａ抗体
JPWO2009051201A1 (ja) 抗ｂｓｔ２抗体
UA129672C2 (uk) Антитіло до trem-1 та його застосування
US20240175873A1 (en) Methods for the diagnosis and treatment of t cell-lymphomas
JP5526407B2 (ja) 抗ａｄａｍ−１５抗体及びその利用
CN107849139A (zh) 与人crth2特异性结合的抗体
CN103025354A (zh) 自身免疫疾病和变应性疾病的治疗药
WO2024003310A1 (en) Methods for the diagnosis and treatment of acute lymphoblastic leukemia
EP4227413A1 (en) Novel anti-sugar chain antibody and use thereof
US20050202029A1 (en) Family of cystatin-related chemoattractant proteins
JP2022506108A (ja) グリコシル化ＡｐｏＪに特異的な抗体およびその使用
CN115947855B (zh) 抗cd24抗体的制备及其用途
WO2024023283A1 (en) Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
EP4602372A1 (en) Cd81 as a biomarker and biotarget in t-cell malignancies
EP4558823A1 (en) Garp as a biomarker and biotarget in t-cell malignancies
WO2023198648A1 (en) Methods for the diagnosis and treatment of t-cell malignancies
WO2023198874A1 (en) Methods for the diagnosis and treatment of t cell-lymphomas
Lent et al. Elevated FcyRII expression and aberrant TNF-a production by mature DC from patients with active rheumatoid arthritis (RA)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141111